What is MS?
Multiple Sclerosis is a chronic autoimmune disease, which attacks myelin - the substance that surrounds and insulates the nerve fibers — as well as the nerve fibers themselves.
MS impacts patients' motricity, balance, vision and evolves by relapses. In 85% of cases, patients develop handicaps and a loss of motricity.
More than 2.5 million people worldwide are affected by MS. Its treatment costs are estimated between 15 and 20 billion euros per year in Europe. Currently, the means used to follow and treat MS are not optimized. The patient assessment relies on a score coming from medical gold standards tests / questionnaires (MSFC, EDSS...) hard and lengthy to conduct and presenting several limits.
DAMS, an innovation in MS assessment
Ad Scientiam has developed DAMS, which innovates in MS self-assessment and aims at becoming THE new market standard.
In addition, several digital functionalities will support patients (symptom checker, adherence, tutorials...)
Self-assessment tests developed were built from the MSFC method, co-created with a board of experts and patients, and validated through large scale clinical trial. They will evaluate vision, cognition, dexterity and walking.
Finally, collected real-world data will allow future analytics studies and continuous improvement of algorithms.
This program has been conducted with the institutional support of Roche France, a medical board of neurologists and leading patients and clinicians associations (French Federation of Neurology, OFSEP, ARSEP)
A Proof-of-Concept study was conducted in 2016 on DAMS (TRL 6: System/subsystem model or prototype demonstration in a relevant environment), demonstrating a strong correlation between DAMS and MSFC scores.